Hypotension caused by therapeutic doses of venlafaxine:: case report and proposed pathophysiological mechanisms

被引:6
作者
Alexandrino-Silva, Clovis [1 ]
Nadalini Maua, Fernando Henrique [1 ]
de Andrade, Arthur Guerra [2 ,3 ]
de Toledo Ferraz Alves, Tania Correa [2 ,3 ]
机构
[1] Fdn ABC, Sch Med, BR-09060650 Santo Andre, SP, Brazil
[2] Fundacao ABC, Sch Med, Santo Andre, Brazil
[3] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil
关键词
hypotension; venlafaxine; pathophysiological mechanisms; therapeutic doses; hypertension;
D O I
10.1177/0269881107076403
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although venlafaxine is usually associated with modest increases in blood pressure and not so often clinical hypertension, there are a few reported cases of hypotension related to overdoses of this specific antidepressant. The case study of a young female patient with a history of Major Depressive Disorder who initiated treatment with venlafaxine 75 mg/day and developed hypotension when the dosage was titrated up to 225 mg/day is described. The patient did not present comorbid diseases nor use other medication. A temporal association and a dose-dependent relationship between the hypotension and the use of venlafaxine is shown. To the best of the knowledge of the authors, this is the first case report that specifically associates regular doses of venlafaxine with the presence of hypotension. A pathophysiological mechanism is proposed, involving the participation of presynaptic alpha2-adrenergic receptors and the presence of a possible genetic polymorphism of cytochrome P4502D6, which is associated with lower drug metabolization, to explain the relationship between venlafaxine in regular dosage and development of hypotension.
引用
收藏
页码:214 / 216
页数:3
相关论文
共 14 条
[1]
Fatal venlafaxine overdose [J].
Benham, NDG .
MEDICAL JOURNAL OF AUSTRALIA, 1998, 169 (08) :445-+
[2]
Cardiovascular and neurological toxicity of venlafaxine [J].
Blythe, D ;
Hackett, LP .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1999, 18 (05) :309-313
[3]
Severe adverse drug reactions of antidepressants:: Results of the German multicenter drug surveillance program AMSP [J].
Degner, D ;
Grohmann, R ;
Kropp, S ;
Rüther, E ;
Bender, S ;
Engel, RR ;
Schmidt, LG .
PHARMACOPSYCHIATRY, 2004, 37 :S39-S45
[4]
Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation [J].
Dorne, JLCM .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (06) :609-620
[5]
Clinical and pharmacological significance of α2-adrenoceptor polymorphisms in cardiovascular diseases [J].
Flordellis, C ;
Manolis, AS ;
Scheinin, M ;
Paris, H .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 97 (03) :367-372
[6]
Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting [J].
Grasmäder, K ;
Verwohlt, PL ;
Rietschel, M ;
Dragicevic, A ;
Müller, M ;
Hiemke, C ;
Freymann, N ;
Zobel, A ;
Maier, W ;
Rao, ML .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (05) :329-336
[7]
Evidence of the dual mechanisms of action of venlafaxine [J].
Harvey, AT ;
Rudolph, RL ;
Preskorn, SH .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (05) :503-509
[8]
Cardiovascular changes associated with venlafaxine in the treatment of late-life depression [J].
Johnson, Ellyn M. ;
Whyte, Ellen ;
Mulsant, Benoit H. ;
Pollock, Bruce G. ;
Weber, Elizabeth ;
Begley, Amy E. ;
Reynolds, Charles F. .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (09) :796-802
[9]
KOKAN L, 1996, ANN EMERG MED, V27, P815
[10]
QT interval prolongation associated with venlafaxine administration [J].
Letsas, K ;
Korantzopoulos, P ;
Pappas, L ;
Evangelou, D ;
Efremidis, M ;
Kardaras, F .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 109 (01) :116-117